BridgeBio Pharma Inc

BridgeBio Pharma Inc

BBIO

Get informed when a big investor buys or sells

+ Follow
Market Cap$15.96B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
BridgeBio Pharma IncBridgeBio Pharma Inc-22.8-28%27.7-1
$107.93

Target Price by Analysts

30.1% upsideBridgeBio Pharma Target Price DetailsTarget Price
$-76.74

Current Fair Value

192.5% downside

Overvalued by 192.5% based on the discounted cash flow analysis.

Share Statistics

Market cap$15.96 Billion
Enterprise Value$17.78 Billion
Dividend Yield$- (-)
Earnings per Share$-3.79
Beta0.98
Outstanding Shares195,785,884

Return

Return on Equity27.68%ROE
Return on Assets-57.20%
Return on Invested Capital-186.30%

Valuation & Multiples

P/E Ratio-22.77P/E Ratio
PEG139.49PEG
Price to Sales27.66Price to Sales
Price to Book Ratio-6.38Price to Book Ratio
Enterprise Value to Revenue26.23
Enterprise Value to EBIT-29.22
Enterprise Value to Net Income-26
Total Debt to Enterprise0.14
Debt to Equity-0.99Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
August 10, 2026
EPS Estimate
$-0.58
Average shareholder expectation
Revenue Estimate
$220.91 M
Average shareholder expectation

Next Earnings Call

Expected Date
October 28, 2026
EPS Estimate
$-0.67
Average shareholder expectation
Revenue Estimate
$267.31 M
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.1652▲ 1.48%
Total Calls11,050,000▲ 6.51%
Total Puts1,825,800▲ 17.02%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %100.02%▲ 0.10%
Total Invested$14.50B▲ 0.59%
Investors Holding501▲ 10.00%

ESG Score

No data

About BridgeBio Pharma Inc

CEO: Neil Kumar